Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Topical ruxolitinib and oral minoxidil together can regrow hair in certain types of hair loss.

Tacrolimus is a better option than cyclosporine due to fewer side effects.

CDK4/6 inhibitors affect safety and quality of life differently, requiring careful use.

Baricitinib and deuruxolitinib are effective for treating alopecia areata, but their efficacy depends on the dose.

Ritlecitinib is more effective and cost-efficient than baricitinib for severe alopecia areata.

EGFR inhibitors can cause skin eruptions different from acne, needing specific management.

Advocacy groups should avoid marketing partnerships that may imply drug endorsements.

High TSPEAR levels in colorectal cancer predict worse outcomes.

Don't combine abiraterone and spironolactone for prostate cancer treatment as it may worsen the disease.

Trodelvy™ helped some patients with advanced breast cancer, but had side effects.

Pembrolizumab can cause unusual eyelash growth, but it may still be worth continuing if cancer treatment is effective.

A new method quickly detects hair changes from EGFR inhibitors using a microscope.

Skin reactions from cancer treatments might predict how well the treatments work.

Avacopan may cause unexpected side effects, so early monitoring is important.

Topical tofacitinib may help regrow hair in children with alopecia totalis.

Oral tofacitinib is more effective than oral minoxidil for treating alopecia areata.

High TSPEAR levels in colorectal cancer predict worse outcomes.

Lack of KSR1 stops certain skin tumors in mice.

Topical JAK inhibitors may help treat alopecia universalis by promoting hair regrowth.

A patient's grey hair regained color during treatment with adalimumab.

Baricitinib is effective and safe for treating severe alopecia areata for up to 5 years.

A woman with rheumatoid arthritis lost all her hair during adalimumab treatment, and stopping the drug didn't help.

Baricitinib is effective and safe for treating severe alopecia areata, promoting significant hair regrowth.

Baricitinib helps grow eyebrows and eyelashes in severe alopecia areata patients.

A woman's hair loss worsened after starting hepatitis C treatment due to immune changes in her hair follicles.

JAK inhibitors like tofacitinib may effectively treat Alopecia Areata.

Erlotinib can cause hair loss and texture changes.

Blocking S100A8 can reduce chemotherapy-induced hair loss.

Drug approvals slowed in 2Q22, but notable drugs like Amvuttra, Camzyos, and Olumiant were approved.

A JAK1 variant causes hair loss, skin issues, and thyroid disease, but treatment with a specific inhibitor can help.